Interventional device developer Boston Scientific said it has received the European CE Mark for its Taxus Liberté paclitaxel-eluting stent system.
The Natick, MA-based firm reported that it plans to launch the product in European markets and other key CE Mark-dependent international markets. The Taxus Liberté was launched earlier this year in select international markets and is expected to launch in the U.S. in 2006, Boston Scientific said.
By AuntMinnie.com staff writers
September 8, 2005
Related Reading
Boston Scientific makes hurricane relief donation, September 1, 2005
FDA warns Boston Scientific, August 24, 2005
Boston Scientific Q2 sales edge up, July 19, 2005
Boston Scientific nets patent legal win, July 4, 2005
Jury favors J&J over Boston Scientific on stent patent, June 22, 2005
Copyright © 2005 AuntMinnie.com
